Get the Stockscreener App
7.51
5.63%
0.40
Certara Inc stock is traded at $7.51, with a volume of 5.62M.
It is up +5.63% in the last 24 hours and up +38.31% over the past month.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
See More
Previous Close:
$7.11
Open:
$7.13
24h Volume:
5.62M
Relative Volume:
1.42
Market Cap:
$1.17B
Revenue:
$419.75M
Net Income/Loss:
$-15.10M
P/E Ratio:
-78.80
EPS:
-0.0953
Net Cash Flow:
$63.10M
1W Performance:
+8.37%
1M Performance:
+38.31%
6M Performance:
-24.90%
1Y Performance:
-31.60%
1-Day Range:
$7.13
$7.60
1-Week Range:
$6.69
$7.60
52-Week Range:
$4.45
$13.88
Certara Inc Stock (CERT) Company Profile
Name
Certara Inc
Sector
Industry
Phone
(415) 237-8272
Address
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT vs VEEV, BTSG, HQY, TEM, TXG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
7.51 | 1.17B | 419.75M | -15.10M | 63.10M | -0.0953 |
VEEV
Veeva Systems Inc
|
186.24 | 30.25B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
72.91 | 14.31B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
94.64 | 7.91B | 1.34B | 230.70M | 440.96M | 2.6695 |
TEM
Tempus Ai Inc
|
42.69 | 7.69B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
46.27 | 5.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-27-26 | Downgrade | Craig Hallum | Buy → Hold |
| Jan-06-26 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-21-25 | Initiated | Rothschild & Co Redburn | Buy |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-29-25 | Initiated | Craig Hallum | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-08-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Upgrade | UBS | Neutral → Buy |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-04-24 | Initiated | JMP Securities | Mkt Perform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Aug-22-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-10-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-08-22 | Initiated | Berenberg | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-01-22 | Initiated | Piper Sandler | Overweight |
| Jan-11-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-23-21 | Initiated | Robert W. Baird | Outperform |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-06-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Neutral |
| Jan-05-21 | Initiated | Jefferies | Hold |
| Jan-05-21 | Initiated | William Blair | Outperform |
View All
Certara Inc Stock (CERT) Latest News
Certara, Inc. (CERT) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Technical Reactions to CERT Trends in Macro Strategies - Stock Traders Daily
How Certara’s NVIDIA AI Partnership Could Reshape CERT’s Long-Term Drug Development Narrative - webull.com
Certara Inc. (CERT) Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesEarnings Sentiment Score - dars.gov.et
Certara Inc. (CERT) Slides 4.8% as Shares Test Key Support LevelsCollar Trade - dars.gov.et
Certara files Form 3 for interim CFO Mohammed Faiz initial beneficial ownership statement - Bitget
Certara (CERT) interim CFO discloses stock, RSU and PSU holdings - Stock Titan
Why Did CERT Stock Fall Today? - Stocktwits
Certara to report Q2 2026 financial results on August 4 - scanx.trade
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026 - The Manila Times
Certara sets Aug. 4 call to discuss second-quarter results - Stock Titan
BlackRock, Inc.'s Strategic Acquisition of Certara Inc. Shares - GuruFocus
Pomerantz investigates Certara investors over p... - Pluang
Dimensional Fund Advisors details Certara Inc (CERT) 3.9% ownership position - Stock Titan
What Certara (CERT)'s NVIDIA BioNeMo Partnership Means For Shareholders - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc.CERT - PR Newswire
BlackRock (CERT) discloses 18.0M shares; 11.6% ownership reported - Stock Titan
AI Chips TodayCertara-NVIDIA Partnership Revolutionizes AI in Drug Development - Yahoo Finance
Certara partners with Nvidia to integrate AI agents into drug development platform - Investing.com UK
Nvidia Powers AI Agent Strategies for Certara, Silo PharmaNVIDIA (NASDAQ:NVDA) - Benzinga
Certara teams up with Nvidia to strengthen AI platform with BioNeMo toolkit (CERT) - Yahoo Finance
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit - The Manila Times
Certara Accelerates Drug Discovery and Development With NVIDIA BioNeMo Agent Toolkit - 富途牛牛
Certara, Silo Pharma advance AI strategies with Nvidia initiatives - scanx.trade
Price to earnings forward of Certara, Inc. – HAM:700 - TradingView
Enterprise value to revenue forward of Certara, Inc. – NASDAQ:CERT - TradingView
Price to sales forward of Certara, Inc. – HAM:700 - TradingView
Certara Inc (NASDAQ: CERT) Share Price, CERT Stock News, CERT Share Price & Updates - Kalkine
Is Certara (CERT) Quietly Recasting Its Small-Cap Identity Around Biosimulation Advisory Leadership? - Yahoo Finance
Does Certara (CERT) Joining the Russell 2000 Recast Its Biosimulation Investment Narrative? - simplywall.st
CERT Q1 2026 Earnings: EPS Misses Estimates but Stock Rises 2.75%Share Dilution Risk - DonanımHaber
Trading the Move, Not the Narrative: (CERT) Edition - Stock Traders Daily
William Blair Maintains Certara(CERT.US) With Hold Rating - Moomoo
Should You Investigate Certara, Inc. (NASDAQ:CERT) At US$6.36? - Moomoo
Certara, Inc. (CERT) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Pomerantz investigates Certara after revenue drop and CFO exit - scanx.trade
Certara, Inc.(NasdaqGS: CERT) added to Russell 2000 Index - marketscreener.com
Certara, Inc.(NasdaqGS: CERT) dropped from Russell Midcap Value Benchmark - marketscreener.com
Certara Inc. (CERT) Rallies 8.9% – Key Support and Resistance Levels in FocusVirgin POC - dars.gov.et
Enterprise value to EBITDA forward of Certara, Inc. – NASDAQ:CERT - TradingView
Certara, Inc.(NasdaqGS: CERT) dropped from Russell 1000 Dynamic Index - marketscreener.com
Enterprise value to EBIT forward of Certara, Inc. – NASDAQ:CERT - TradingView
Certara, Inc.(NasdaqGS: CERT) dropped from Russell Midcap Index - marketscreener.com
Price to book forward of Certara, Inc. – NASDAQ:CERT - TradingView
Price to book forward of Certara, Inc. – BMV:CERT - TradingView
Price to earnings forward of Certara, Inc. – BMV:CERT - TradingView
[Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Certara, Inc. Actuals & Estimates (NASDAQ:CERT) - TradingView
CERT Forecast — Price Target — Prediction for 2027 - TradingView
Certara Q1 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterAnalyst Consensus Shift - dars.gov.et
Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-Risk Investment and Accelerate Development - marketscreener.com
Certara Inc Stock (CERT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.99%
2.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):